1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GeoVax Labs, Inc.

GeoVax Labs, Inc.

GOVXW
GeoVax Labs, Inc.US flagNASDAQ Capital Market
0.00
USD
+0.00
- -
88,758.00Market Cap
GeoVax Labs, Inc.
GOVXW
(NASDAQ Capital Market)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
5
5
3
2
1
- -
1
1
1
1
2
- -
- -
- -
4
2
1
Sales/Revenue/Turnover
-53.44
-47.94
-80.49
-94.7
-310.05
-629.5
-394.9
-202.22
-266.06
-201.76
-154.46
-4,862.72
-17,207.47
- -
-635.83
-869.34
-2,523.43
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
-2
-2
-2
-3
-3
-3
-2
-3
-2
-3
-19
-14
-26
-25
-21
-21
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.98
-47.9
-80.35
-94.51
-309.59
-628.22
-394.7
-201.82
-265.79
-201.6
-162.21
-4,817.19
-17,198.35
- -
-631.98
-862.34
-2,507.27
Profit Margin (%)
1
- -
1
2
1
1
- -
- -
-1
-2
9
6
24
4
5
3
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
LT Debt
2
1
1
3
1
1
- -
- -
-1
-2
10
4
27
6
5
4
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
2
3
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
7
5
2
Cash, Cash Equivalents & STI
5
3
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-40.84%
68.09%
-24.23%
Free Cash Flow
42.13%
74.75%
-12.94%
Net Income, GAAP
59.4%
114.13%
-14.11%
Sales/Revenue/Turnover
- -
- -
-37.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
3
1
4
2025
2
1
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Xintela AB (publ) (XINT.ST)
SanBio Company Limited (SNBIF)
Protagenic Therapeutics, Inc. (PTIX)
Polyphor AG (POLN.SW)
Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
Puma Biotechnology, Inc. (PBYI)
Business
GeoVax Labs, Inc. (Nasdaq: GOVX; GOVXW) is a clinical-stage biotechnology company developing novel vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary modified vaccinia Ankara virus-like particle and gene-directed enzyme prodrug therapy platforms; its lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine in three Phase 2 clinical trials evaluating it as a primary vaccine for immunocompromised patients including those with hematologic cancers and chronic lymphocytic leukemia, and as a durable booster for healthy adults previously vaccinated with mRNA products; additional preventive vaccines target Mpox and smallpox with planned Phase 3 evaluation per recent EMA guidance, hemorrhagic fever viruses including Ebola Zaire, Ebola Sudan, Marburg and Lassa, malaria, Zika virus and human immunodeficiency virus; in oncology, lead product Gedeptin, an oncolytic gene therapy with Orphan Drug Designation for oral and pharyngeal cancers, has completed a multicenter Phase 1/2 trial for advanced head and neck cancers and preclinical expansion to additional solid tumors such as triple negative breast cancer and cutaneous malignancies in combination with checkpoint inhibitors like pembrolizumab. The company, founded in 1988 and headquartered in Smyrna, Georgia, maintains U.S.-focused operations with worldwide intellectual property rights, collaborations including the National Institutes of Health and U.S. Department of Defense, and recent BARDA-supported revenue growth to $2.5 million in Q2 2025; latest developments encompass a September 2025 $2.5 million registered direct offering for clinical advancement, September 2025 preclinical expansion of Gedeptin development leveraging KEYNOTE-689 checkpoint data with Phase 2 initiation for head and neck cancer planned for H2 2026, and ongoing enrollment in GEO-CM04S1 Phase 2 trials with new sites added.